Journal of the American Academy of Dermatology
Volume 61, Issue 1 , Pages 112-116 , July 2009

A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome

  • Jennifer M. Gardner, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Camille E. Introcaso, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Sunita D. Nasta, MD

      Affiliations

    • Department of Medicine, Hematology Oncology Division, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Ellen J. Kim, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Carmela C. Vittorio, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Alain H. Rook, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Corresponding Author InformationCorrespondence to: Alain H. Rook, MD, Hospital of the University of Pennsylvania, 3600 Spruce St, 2 Maloney Bldg, Philadelphia, PA 19146.

References 

  1. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest. 2005;115:798–812
  2. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350:1978–1988
  3. Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N, et al. Paucity of Foxp3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia. 2006;20:1123–1129
  4. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev. 2007;33:146–160
  5. McGinnis KS, Ubriani R, Newton S, Junkins-Hopkins JM, Vittorio CC, Kim EJ, et al. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. Arch Dermatol. 2005;141:1176–1177
  6. Shapiro M, Rook AH, Lehrer MS, Junkins-Hopkins JM, French LE, Vittorio CC. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVA cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47:956–961
  7. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007;16:1111–1120
  8. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–39
  9. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115
  10. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74:659–671
  11. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T cell lymphoma. Clin Cancer Res. 2007;13:2318–2322
  12. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1282–1284
  13. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541–5552
  14. Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25– naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–1886

 Funding sources: None.

 Disclosure: Dr Rook has lectured at events sponsored by Merck. Dr Kim was a study site investigator for a clinical trial involving vorinostat from 2004 to 2005. Drs Gardner, Introcaso, Nasta, and Vittorio have no conflicts of interest to declare.

 Reprints not available from the authors.

PII: S0190-9622(08)02460-2

doi: 10.1016/j.jaad.2008.11.889

Journal of the American Academy of Dermatology
Volume 61, Issue 1 , Pages 112-116 , July 2009

Article Tools

* Image Usage & Resolution